Sikander Ailawadhi MD
Hematologic Oncology
Professor of Medicine, Lead for International Cancer Center, Divisions of Hematology/Oncology and Cancer Biology, Department of Medicine
Join to View Full Profile
4500 San Pablo Road SJacksonville, FL 32224
Dr. Ailawadhi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University at BuffaloFellowship, Hematology and Medical Oncology, 2006 - 2008- University at BuffaloResidency, Internal Medicine, 2003 - 2006
Delhi University College of Medical SciencesClass of 2001
Certifications & Licensure
FL State Medical License 2013 - 2028
TN State Medical License 2020 - 2023
CA State Medical License 2007 - 2013
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Powerchart (Image Results), Cerner Corporation, 2014-2015, 2017
- CMS Meaningful Use Stage 1 Certification FirstNet (Image Results), Cerner Corporation, 2014-2015, 2017
- CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2014-2015, 2017
Clinical Trials
- Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting Start of enrollment: 2010 Dec 02
- Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
- Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant Start of enrollment: 2017 Mar 10
Publications & Presentations
PubMed
- POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia.Saurabh Zanwar, Jithma Abeykoon, Shirley D'Sa, Damien Roos-Weil, Dirk R Larson
Blood Advances. 2026-04-14 - Diagnosis and management of immune effector cell-associated enterocolitis (IEC-EC) following ciltacabtagene autoleucel.Kenneth Jc Lim, Hee Eun Lee, Zongming Eric Chen, Adam Bledsoe, Ricardo D Parrondo
Blood Advances. 2026-04-10 - Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myeloma.Hans C Lee, Wouter J Plattel, Simon J Harrison, Douglas W Sborov, Suzanne Lentzsch
Blood. 2026-04-08
Journal Articles
- Targeting CD38 with Daratumumab Is Lethal to Waldenström Macroglobulinaemia CellsRichard Furman, Stephen M Ansell, Sikander Ailawadhi, Thomas E Witzig, Vivek Roy, Taimur Sher, Liuyan Jiang, British Journal of Haematology
- Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
Abstracts/Posters
- Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect¬ MM R...Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Population-Based Analysis of Predictors of Survival and Trends in Outcomes of Elderly Patients with Multiple Myeloma (MM)Sikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined SignificanceSikander Ailawadhi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Racial Disparities in Multiple Myeloma CareASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- Evolving Real-World Treatment Patterns in Patients with Newly-Diagnosed Multiple Myeloma (NDMM) in the United States (U.S.)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
Significant Treatment Advances in Multiple Myeloma Presented at ASCO 2025June 17th, 2025- Ask Me Anything: LymphomaMarch 25th, 2025
- Press Release: New Sarclisa Subcutaneous Formulation Met Co-Primary Endpoints in the IRAKLIA Phase 3 Study in Multiple MyelomaJanuary 9th, 2025
Professional Memberships
- Member
- Member
Other Languages
- Hindi
External Links
- Mayo Clinic Profilehttps://www.mayoclinic.org/biographies/ailawadhi-sikander-m-d/bio-20087330
- Patient Referralhttps://www.mayoclinic.org/medical-professionals/provider-relations/refer-patient
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
